Coronado Biosciences Granted First U.S. Patent Covering CNDO-109
September 05, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., Sept. 5, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
Coronado Biosciences to Present at Upcoming Investor Conferences
August 30, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., Aug. 30, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
Coronado Biosciences Secures $15 Million Loan Facility From Hercules Technology Growth Capital
August 29, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., Aug. 29, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences to Moderate Diabetes Panel at the 8th Annual Swedish-American Life Science Summit in Stockholm
August 22, 2012 07:01 ET
|
Coronado Biosciences
BURLINGTON, Mass., Aug. 22, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Dr. Harlan Weisman Elected to Board of Directors of Coronado Biosciences
August 16, 2012 16:05 ET
|
Coronado Biosciences
BURLINGTON, Mass., Aug. 16, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Initiates Phase 2 Clinical Trial of TSO for the Treatment of Crohn's Disease
August 14, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., Aug. 14, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
Coronado Biosciences Reports Financial Results for the Second Quarter Ended June 30, 2012
August 08, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., Aug. 8, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
Coronado Biosciences Announces Initiation of Investigator-Initiated Study Evaluating TSO in Ulcerative Colitis
August 07, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., Aug. 7, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences to Present at the Wedbush Life Sciences Management Access Conference
August 06, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., Aug. 6, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
Coronado Biosciences to Report Second Quarter 2012 Financial Results
August 01, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., Aug. 1, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...